Table 1 Demographic and clinicopathologic data of all patients
|  | All patients | Patients with NAC N = 12 | Patients without NAC N = 125 | p-value | |
|---|---|---|---|---|---|
Age | 47.39 ± 8.01 | 50.9 ± 6.8 | 47.1 ± 8.1 | 0.136 a | |
32–58 |  |  | |||
Age subgroups | 30–39 | 35 (25.5) | 2 (16.7) | 33 (26.4) | 0.686 b |
40–49 | 37 (27) | 3 (25) | 34 (27.2) | ||
≥ 50 | 65 (47.4) | 7 (58.3) | 58 (46.4) | ||
Tumor size | 2.9 ± 1.16 | 4.18 ± 1.16 | 2.35 ± 1.1 | <0.001 a | |
Range | 1–6 |  |  | ||
<  4 cm | 101 (73.7) | 4 (33.3) | 97 (77.6) | 0.003 b | |
≥ 4 cm | 36 (26.3) | 8 (66.7) | 28 (22.4) | ||
Tumor nipple distance | 3.38 ± 0.92 | 1.95 ± 0.72 | 3.52 ± 0.84 | <0.001a | |
Range | 1.4–6 |  |  | ||
<  2 cm | 6 (4.4) | 4 (33.3) | 2 (1.6) | <0.001 ɑ | |
2 – < 2.5 cm | 11 (8) | 2 (16.7) | 9 (7.2) | ||
2.5 - <  3 cm | 4 (2.9) | 3 (25) | 1 (0.8) | ||
3 - <  4 cm | 79 (57.7) | 1 (8.3) | 78 (62.4) | ||
≥ 4 cm | 37 (27) | 2 (16.7) | 35 (28) | ||
Tumor site | Upper inner | 22 (16.1) | 1 (8.3) | 21 (16.8) | 0.470 b |
Upper outer | 26 (19.1) | 2 (16.7) | 24 (19.2) | ||
Lower inner | 31 (22.6) | 1 (8.3) | 30 (24) | ||
Lower outer | 7 (5.1) | 1 (8.3) | 6 (4.8) | ||
Central | 51 (37.2) | 7 (58.3) | 44 (35.2) | ||
Histologic type | DCIS | 32 (23.4) | 5 (41.7) | 27 (21.6) | 0.033 b |
IDC | 37 (27) | 5 (41.7) | 32 (25.6) | ||
LCIS | 43 (31.4) | 1 (8.3) | 42 (33.6) | ||
ILC | 25 (18.2) | 1 (8.3) | 24 (19.2) | ||
histologic grade | Grade I | 63 (46) | 2 (16.7) | 61 (48.8) | 0.003 b |
Grade II | 39 (28.5) | 2 (16.7) | 37 (29.6) | ||
Grade III | 35 (25.5) | 8 (66.7) | 27 (21.6) | ||
Lymph node involvement | Positive | 39 (28.5) | 9 (75) | 30 (24) | 0.001b |
Lymph node numbers | <  4 | 13 (9.5) | 0 (8.3) | 13 (43.3) | <0.001 ɑ |
4 - < 10 | 14 (10.2) | 1 (11.1) | 13 (43.3) | ||
≥ 10 | 12 (8.8) | 8 (88.9) | 4 (13.3) | ||
Staging | II | 80 (58.4) | 3 (27.3) | 77 (61.6) | 0.032 b |
III | 57 (41.6) | 8 (72.7) | 49 (38.9) | ||
Multifocal tumor | 13 (9.5) | 4 (33.3) | 9 (7.2) | 0.016 b | |
Multicenteric | 14 (10.2) | 5 (41.7) | 9 (7.2) | 0.003 b | |
Lymphovascular invasion | 21 (15.3) | 5 (41.7) | 16 (12.8) | 0.020 b | |
Estrogen receptor status | 13 (9.5) | 6 (50) | 7 (5.6) | <0.001b | |
Progesterone receptor status | 12 (8.8) | 7 (58.3) | 5 (4) | <0.001b | |
HER status | 17 (12.4) | 7 (58.3) | 10 (8) | <0.001b | |